leadf
logo-loader
viewAdial Pharmaceuticals Inc

Adial Pharmaceuticals making progress with alcohol use disorder drug

Adial Pharmaceuticals Inc (NASDAQ:ADIL) CEO William Stilley spoke with Proactive Investors at the MicroCap Conference in New York.

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder using its lead investigational new drug product, AD04, a selective serotonin-3 antagonist.

Quick facts: Adial Pharmaceuticals Inc

Price: 1.92 USD

NASDAQ:ADIL
Market: NASDAQ
Market Cap: $27.63 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

CO2 GRO sees 20% higher pepper yields though 10 weeks of Hidroexpo Feasibility

CO2 GRO (CVE: GROW- OTCQB: BLONF) Vice President of Sales and Strategic Alliances Aaron Archibald joined Steve Darling from Proactive to bring details the company has seen very good results from their CO2 Delivery Solution commercial feasibility on greenhouse-grown peppers with Hidroexpo in...

22 hours, 53 minutes ago

2 min read